HBV-IN-14
Selected Variant
HY-144045
Size: 1 Each
HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA) . cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5) [1].
Product Specifications
CAS Number
2712529-19-4
UNSPSC
12352005
Target
DNA/RNA Synthesis; HBV
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/hbv-in-14.html
Solubility
10 mM in DMSO
Smiles
O=C1C=C(C2=CC=C(C=C2)OCCO[C@H]3C[C@](C)(C3)C(O)=O)N=C4N1C=CC=C4Cl
Molecular Formula
C22H21ClN2O5
Molecular Weight
428.87
References & Citations
[1]Lifang Wu, et al. Pyridopyrimidinones. Patent WO2021190502A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
N-Cadherin / Cadherin-2 / CD325 (NCAD) (CDH2/1573), CF647 conjugate, 0.1mg/mL
P55;50 EBV-Early Antigen (1108-1), CF740 conjugate, 0.1mg/mL
Cytokeratin, Basic (Type II or HMW) (KRTH/2147R), CF405S conjugate, 0.1mg/mL
Anti-COX6B1 Antibody Picoband®, APC Conjugate
